Reasons for discontinuation of injectable diabetes medications: wave 2

Trial description: Patients with type 2 diabetes mellitus (T2DM) who are treated with currently marketed glucagon-like peptide-1 (GLP-1) agonists had a higher rate of non-persistence (discontinuation) than patients on other anti-diabetic agents. This study is exploratory in nature with a primary goal of describing which characteristics are most commonly associated with discontinuing injectable T2DM therapy. The primary objective of this study is to identify the self-reported reasons for non-persistence among subjects initiating an injectable diabetes medication and to describe the decision-making process for discontinuation. The secondary objectives include describing perceived value of patient support programs and identifying differences between continuers and discontinuers in terms of perceived or experienced barriers to taking the medications. Subjects for this study will be recruited from Harris Interactive’s Chronic Illness Panel (CIP) and/or other third‐party online panels. The study design is a cross-sectional, internet-based survey.